Adakveo ‘Important’ and Safe New Treatment for VOC Crises in Sickle Cell, SUSTAIN Researcher Says
Adakveo (crizanlizumab) is an “important addition” to the care of sickle cell disease, a safe and effective therapy that works against painful vaso-occlusive crises (VOCs) in SCD patients and is likely do so over the long term, said the doctor who led the clinical trial that…